Title: Secondary hyperparathyroidism

Abstract

Secondary hyperparathyroidism (SHPT), which refers to compensatory hyperparathyroid hormone secretion caused by calcium ion balance disturbance, is one of the most common complications of chronic kidney disease (CKD). According to epidemiological survey statistics, the prevalence rate of chronic kidney disease in China is 10.8%, and it is on the rise. According to incomplete statistics, there are about 119.5 million chronic kidney disease patients in China. With the continuous progress of dialysis technology, the survival of CKD patients has been significantly improved, but the incidence of SHPT gradually increases with the increase of dialysis time, and about 32% of patients with chronic kidney disease eventually develop refractory or severe SHPT. The elevated parathyroid hormone can involve systems throughout the body, leading to multi system complications and adverse clinical events such as malnutrition, anemia, calcification of blood vessels and heart valves, renal bone disease, restless leg syndrome, pruritus, and ectopic calcification. At present, the main treatment methods for secondary hyperparathyroidism include drug therapy and surgical therapy. The majority of patients with SHPT rely on phosphate binders, active vitamin D sterols, vitamin D receptor activators, and calcium for drug treatment. Subtotal parathyroidectomy or total parathyroidectomy plus auto transplantation is the most widely used surgical treatment. However, it is impossible to determine which surgical method is the most effective. The choice of surgical method always depends on the individual preference of the surgeon and the clinical condition of the patient. The occurrence of SHPT can seriously affect the life of patients and significantly reduce their quality of life. Severe SHPT may even lead to death, so the early diagnosis and treatment of SHPT are very important for dialysis patients with chronic kidney disease, and it needs to arouse extensive attention from the medical community.

Biography

Zheng Shouhua, M.D.,Prof., Chief Physician, master tutor, now works in the First Affiliated Hospital of Zhengzhou University. He has been engaged in thyroid surgery for many years, and studied in Plastic Surgery Hospital of Chinese Academy of Medical Sciences, specializing in medical aesthetic plastic surgery. He once studied in ETSU QUILLEN COLLEGE OF MEDICINE in the United States as an exchange visitor, and also studied the diagnosis and treatment of related diseases in China-Japan Friendship Hospital. Participated in the translation of Zollinger Surgical Atlas, Thyroid Surgery and Controversies in the Field of Thyroid Surgery. Participated in a number of national and provincial scientific research projects, published a number of papers in international surgery journals and SCI journals, and won a number of provincial scientific and technological progress awards. Current research direction: Common and difficult diseases of thyroid gland and parathyroid gland, including malignant tumors, functional abnormalities, etc.